Almirall Advances Pediatric Atopic Dermatitis Treatment with EMA Filing Acceptance
Event summary
- The EMA accepted Almirall's Marketing Authorisation Application for lebrikizumab (Ebglyss) in pediatric atopic dermatitis patients aged 6 months to <18 years.
- Interim results from the ADorable-1 and ADorable-2 studies showed efficacy and safety consistent with adult/adolescent data, meeting primary endpoints.
- Atopic dermatitis typically begins early in life (60% by age 1), creating a significant unmet need for pediatric treatments.
- Almirall holds European rights to lebrikizumab; Eli Lilly retains U.S. and global rights outside Europe.
The big picture
Almirall's filing targets a critical gap in pediatric dermatology, where atopic dermatitis often begins before age 5. The EMA's acceptance validates lebrikizumab's potential to reduce long-term disease burden—a key differentiator in a market increasingly focused on early intervention. With €1.1B in 2025 revenue, Almirall is leveraging its dermatology expertise to expand into high-need pediatric indications.
What we're watching
- Regulatory Timeline
- The pace at which the EMA completes its review will determine when lebrikizumab could become available for younger patients in Europe.
- Commercial Strategy
- How Almirall positions lebrikizumab against competitors like dupilumab (Sanofi/Regeneron) in pediatric atopic dermatitis.
- Global Expansion
- Whether Eli Lilly accelerates parallel filings in other regions, given the unmet need in early-onset atopic dermatitis.
Related topics